Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 4Myasthenia Gravis 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Prolymphocytic 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Erythroblastic, Acute 1Leukemia 1

Interventions

rozanolixizumab 7zilucoplan 6efgartigimod alfa 5eculizumab 4telitacicept 3ravulizumab 3Tacrolimus 3Rituximab 3Amifampridine 3Prednisone 2Mycophenolic Acid 2HBM9161 2satralizumab 1remibrutinib 1iptacopan 1inebilizumab 1Thymectomy 1Sugars 1Steroids 1Sodium Chloride 1Pyridostigmine Bromide 1Prednisolone 1Plasmapheresis 1Leflunomide 1Immunoglobulins, Intravenous 1Hizentra 1Cladribine 1Azathioprine 1Alkalies 1Adrenal Cortex Hormones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Myasthenia Gravis × Cladribine × Clear all
NCT06463587 2026-05-22

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 3 Recruiting
264 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡